This “Polo-Like Kinase 1 (PLK1) Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Polo-Like Kinase 1 (PLK1) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Polo-Like Kinase 1 (PLK1) Inhibitor Understanding
Polo-like kinase 1 (Plk1) is a serine/threonine kinase that is a key regulator of multiple stages of mitotic progression. PLK1 is one of the five members of the PLK family and are found in the nuclei of all dividing cells. PLKs are defined by two conserved features: an N terminal Ser/Thr kinase domain and a C-terminal duplicated Polo-box region. PLK1 is the most extensively studied of five members of the polo-like family and is primarily known for operating as a pleiotropic master regulator of the cell cycle from entry into mitosis to the initiation of cytokinesis. This includes regulating the activity of proteins involved in establishing centromeres, initiating spindle checkpoint signaling and coordinating the activity of the spindle checkpoint. PLK1 inhibition has been shown to cause mitotic block and apoptosis of tumor cells. The potential of PLK1 inhibitors as cancer therapeutic has been widely explored, which resulted in several PLK1 inhibitors in clinical trials following their preclinical successes.
Report Highlights
This segment of the Polo-Like Kinase 1 (PLK1) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Polo-Like Kinase 1 (PLK1) Inhibitor Emerging Drugs
Onvansertib: Cardiff Oncology
Onvansertib is a first-In-class, third-generation, oral and highly-selective PLK1 inhibitor. Onvansertib selectively inhibits PLK1, a proven therapeutic target that is over-expressed in most cancers. Onvansertib works synergistically in combination with chemotherapies and targeted therapeutics. In May 2020, FDA has granted Fast Track designation to onvansertib (PCM-075) for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC).
CYC-140: Cyclacel Pharmaceuticals
CYC140 is a novel, small molecule, selective, ATP-competitive, Plk1 inhibitor. CYC140 shows selective target inhibition, impressive efficacy and cures human tumor xenografts at non-toxic doses. The molecule is in clinical evaluation for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
This segment of the report provides insights about the different Polo-Like Kinase 1 (PLK1) Inhibitor drugs segregated based on following parameters that define the scope of the report.
There are approx. 8+ key companies which are developing the Polo-Like Kinase 1 (PLK1) Inhibitor. The companies which have their Polo-Like Kinase 1 (PLK1) Inhibitor drug candidates in the most advanced stage, i.e. Phase II include, Cardiff Oncology.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Polo-Like Kinase 1 (PLK1) Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Polo-Like Kinase 1 (PLK1) Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polo-Like Kinase 1 (PLK1) Inhibitor drugs.
Geography Covered
- Global coverage
Polo-Like Kinase 1 (PLK1) Inhibitor Understanding
Polo-Like Kinase 1 (PLK1) Inhibitor: Overview
Polo-like kinase 1 (Plk1) is a serine/threonine kinase that is a key regulator of multiple stages of mitotic progression. PLK1 is one of the five members of the PLK family and are found in the nuclei of all dividing cells. PLKs are defined by two conserved features: an N terminal Ser/Thr kinase domain and a C-terminal duplicated Polo-box region. PLK1 is the most extensively studied of five members of the polo-like family and is primarily known for operating as a pleiotropic master regulator of the cell cycle from entry into mitosis to the initiation of cytokinesis. This includes regulating the activity of proteins involved in establishing centromeres, initiating spindle checkpoint signaling and coordinating the activity of the spindle checkpoint. PLK1 inhibition has been shown to cause mitotic block and apoptosis of tumor cells. The potential of PLK1 inhibitors as cancer therapeutic has been widely explored, which resulted in several PLK1 inhibitors in clinical trials following their preclinical successes.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Polo-Like Kinase 1 (PLK1) Inhibitor R&D. The therapies under development are focused on novel approaches for Polo-Like Kinase 1 (PLK1) Inhibitor.
Polo-Like Kinase 1 (PLK1) Inhibitor Emerging Drugs Chapters
This segment of the Polo-Like Kinase 1 (PLK1) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Polo-Like Kinase 1 (PLK1) Inhibitor Emerging Drugs
Onvansertib: Cardiff Oncology
Onvansertib is a first-In-class, third-generation, oral and highly-selective PLK1 inhibitor. Onvansertib selectively inhibits PLK1, a proven therapeutic target that is over-expressed in most cancers. Onvansertib works synergistically in combination with chemotherapies and targeted therapeutics. In May 2020, FDA has granted Fast Track designation to onvansertib (PCM-075) for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC).
CYC-140: Cyclacel Pharmaceuticals
CYC140 is a novel, small molecule, selective, ATP-competitive, Plk1 inhibitor. CYC140 shows selective target inhibition, impressive efficacy and cures human tumor xenografts at non-toxic doses. The molecule is in clinical evaluation for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
Polo-Like Kinase 1 (PLK1) Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Polo-Like Kinase 1 (PLK1) Inhibitor drugs segregated based on following parameters that define the scope of the report.
Major Players working on Polo-Like Kinase 1 (PLK1) Inhibitor
There are approx. 8+ key companies which are developing the Polo-Like Kinase 1 (PLK1) Inhibitor. The companies which have their Polo-Like Kinase 1 (PLK1) Inhibitor drug candidates in the most advanced stage, i.e. Phase II include, Cardiff Oncology.
Phases
This report covers around 8+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Polo-Like Kinase 1 (PLK1) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Polo-Like Kinase 1 (PLK1) Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Polo-Like Kinase 1 (PLK1) Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polo-Like Kinase 1 (PLK1) Inhibitor drugs.
Polo-Like Kinase 1 (PLK1) Inhibitor Report Insights
- Polo-Like Kinase 1 (PLK1) Inhibitor Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Polo-Like Kinase 1 (PLK1) Inhibitor Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Scenario and Emerging Therapies:
- How many companies are developing Polo-Like Kinase 1 (PLK1) Inhibitor drugs?
- How many Polo-Like Kinase 1 (PLK1) Inhibitor drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Polo-Like Kinase 1 (PLK1) Inhibitor?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Polo-Like Kinase 1 (PLK1) Inhibitor therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Polo-Like Kinase 1 (PLK1) Inhibitor and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Oncoheroes Biosciences
- Cyclacel Pharmaceuticals
- Cardiff Oncology
- Onconova Therapeutics
- Sentinel oncology
Key Products
- Volasertib
- CYC-140
- Onvansertib
- Rigosertib
- SOL686
Table of Contents
IntroductionExecutive Summary
Polo-Like Kinase 1 (PLK1) Inhibitor: Overview
- Structure
- Mechanism of Action
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Polo-Like Kinase 1 (PLK1) Inhibitor - Analytical Perspective
In-depth Commercial Assessment
- Polo-Like Kinase 1 (PLK1) Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Polo-Like Kinase 1 (PLK1) Inhibitor Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
- Comparative Analysis
Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Onvansertib: Cardiff Oncology
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
CYC-140: Cyclacel Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Pre-clinical and Discovery Stage Products
- Comparative Analysis
Volasertib: Oncoheroes Biosciences
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Polo-Like Kinase 1 (PLK1) Inhibitor Key Companies
Polo-Like Kinase 1 (PLK1) Inhibitor Key Products
Polo-Like Kinase 1 (PLK1) Inhibitor- Unmet Needs
Polo-Like Kinase 1 (PLK1) Inhibitor- Market Drivers and Barriers
Polo-Like Kinase 1 (PLK1) Inhibitor- Future Perspectives and Conclusion
Polo-Like Kinase 1 (PLK1) Inhibitor Analyst Views
Polo-Like Kinase 1 (PLK1) Inhibitor Key Companies
AppendixList of Tables
Table 1 Total Products for Polo-Like Kinase 1 (PLK1) Inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Polo-Like Kinase 1 (PLK1) Inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Oncoheroes Biosciences
- Cyclacel Pharmaceuticals
- Cardiff Oncology
- Onconova Therapeutics
- Sentinel oncology
